SynthesisNutrients2025
The Controversial Issue of Hypervitaminosis B12 as Prognostic Factor of Mortality: Global Lessons from a Systematic Review and Meta-Analysis.
Synthesis in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo test whether hypervitaminosis B12 is useful for prognosis of all-cause mortality.
methodsMeta-analysis of longitudinal, observational, epidemiologic studies. PubMed, Scopus, Web of Science, Google Scholar, and ProQuest One Academic were searched from inception to 30 June 2024. Studies including humans aged ≥18 years with hypervitaminosis B12, and in whom the outcome variable was all-cause mortality, were included. Two reviewers screened, abstracted (using standardized data collection sheet), and appraised articles (ROBINS-E framework) independently. Frequentist and Bayesian approaches were used for the meta-analysis.
resultsA total of 28 studies were included in the meta-analysis (among the 69,610 participants, 15,815 all-cause deaths were reported). High serum levels of B12 increased marginally the risk of all-cause mortality specifically among chronic diseases (RR = 1.40; 95% IC = 1.05 to 1.85) and hospitalized (RR = 1.57; 95% IC = 1.19 to 2.07). In the meta-regression, these results were not statistically significant. The Bayesian analysis confirmed the risks of the mentioned groups; however, it was limited by the number of studies that contained the necessary information. The methodology applied and the clinical heterogeneity of each included study bring up the idea that artefacts might be involved when mortality is found to be high for hypervitaminosis B12.
conclusionsThis meta-analysis did not show that hypervitaminosis B12 represents a higher risk of all-cause mortality in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.